TFF Pharmaceuticals (Nasdaq:TFFP) - Cotización, noticias y análisis

Resumen de acción TFFP

TFFP fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 67.34%

Análisis de riesgos

No tiene una capitalización de mercado significativa ($8M)

Alta volatilidad del precio de la acción en los últimos 3 meses

Shareholders have been substantially diluted in the past year

Tiene unos ingresos inferiores a 1 millón de dólares ($734K)

+ 1 riesgos adicionales

Competidores de TFF Pharmaceuticals, Inc.

Palisade Bio

NasdaqCM:PALI

US$6.6m

Filament Health

OTCPK:FLHL.F

US$7.8m

Evoke Pharma

NasdaqCM:EVOK

US$4.1m

SciSparc

NasdaqCM:SPRC

US$3.4m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for TFF Pharmaceuticals
Historical stock prices
Current Share Price	US$2.03
52 Week High	US$19.75
52 Week Low	US$2.01
Beta	1.29
1 Month Change	-54.79%
3 Month Change	-66.88%
1 Year Change	-89.28%
3 Year Change	-99.15%
5 Year Change	n/a
Change since IPO	-98.40%

Noticias y actualizaciones recientes

Recent updates

Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

Apr 10

Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

Sep 27

We Think TFF Pharmaceuticals (NASDAQ:TFFP) Needs To Drive Business Growth Carefully

May 17

Here's Why We're Not Too Worried About TFF Pharmaceuticals' (NASDAQ:TFFP) Cash Burn Situation

Jan 06

TFF Pharmaceuticals: Upside Catalysts Starting To Show Up Amid Omicron, But Timidly

Dec 02

Companies Like TFF Pharmaceuticals (NASDAQ:TFFP) Are In A Position To Invest In Growth

Sep 16

TFF Pharmaceuticals: Cautiously Optimistic

Sep 09

TFF Pharma's Platform Is Highly Relevant In The Battle Against The Pandemic

Jul 27

TFF Pharmaceuticals: Looking Attractive At These Prices

Jun 03

Rentabilidad de los accionistas

	TFFP	US Pharmaceuticals	Mercado US
7D	-30.5%	1.1%	0.7%
1Y	-89.3%	9.5%	23.9%

Rentabilidad vs. Industria: TFFP obtuvo unos resultados inferiores a los del sector US Pharmaceuticals , que el año pasado arrojó un rendimiento del 9.5%.

Rentabilidad vs. Mercado: TFFP obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.

Volatilidad de los precios

Is TFFP's price volatile compared to industry and market?
TFFP volatility
TFFP Average Weekly Movement	19.5%
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de TFFP ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de TFFP(19%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2018	19	Harlan Weisman	tffpharma.com

TFF Pharmaceuticals, Inc, una empresa biofarmacéutica en fase clínica, se centra en el desarrollo y la comercialización de medicamentos basados en su plataforma tecnológica patentada Thin Film Freezing (TFF) en Estados Unidos y Australia. Pretende centrarse en el desarrollo de fármacos inhalados en polvo seco para el tratamiento de enfermedades y afecciones pulmonares. Los fármacos candidatos de la empresa son TFF Voriconazole Inhalation Powder, que se encuentra en ensayos clínicos de fase II para el tratamiento y la profilaxis de la aspergilosis pulmonar invasiva; y TFF Tacrolimus Inhalation Powder, que se encuentra en ensayos clínicos de fase II y se utiliza para prevenir el rechazo de trasplantes de pulmón.

Resumen de fundamentos de TFF Pharmaceuticals, Inc.

¿Cómo se comparan los beneficios e ingresos de TFF Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de TFFP
Capitalización bursátil	US$6.29m
Beneficios(TTM)	-US$21.24m
Ingresos (TTM)	US$733.87k

8.6x

Ratio precio-ventas (PS)

-0.3x

Ratio precio-beneficio (PE)

¿Está TFFP sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de TFFP
Ingresos	US$733.87k
Coste de los ingresos	US$11.97m
Beneficio bruto	-US$11.24m
Otros gastos	US$10.00m
Beneficios	-US$21.24m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-6.86
Margen bruto	-1,531.39%
Margen de beneficio neto	-2,894.68%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado TFFP a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción TFFP

Recompensas

Análisis de riesgos

Competidores de TFF Pharmaceuticals, Inc.

NasdaqCM:PALI

US$6.6m

OTCPK:FLHL.F

US$7.8m

NasdaqCM:EVOK

US$4.1m

NasdaqCM:SPRC

US$3.4m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787396 million.

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787396 million.

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787505 million.

TFF Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2024

TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions

New major risk - Market cap size

Recent updates

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787396 million.

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787396 million.

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787505 million.

TFF Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2024

TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions

New major risk - Market cap size

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 39%

No longer forecast to breakeven

TFF Pharmaceuticals, Inc. Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (Tff VORI) Clinical Programs

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.18 million.

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.18 million.

TFF Pharmaceuticals, Inc. Announces Update on Clinical Programs

New major risk - Share price stability

TFF Pharmaceuticals, Inc. to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis At the 11Th Advances Against Aspergillosis & Mucormycosis & Mucromycosis Conference

Forecast to breakeven in 2026

New minor risk - Profitability

TFF Pharmaceuticals, Inc. Appoints Thomas B. King to Board of Directors

TFF Pharmaceuticals, Inc. Appoints Catherine Lee to its Board of Directors

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $35 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 40%

TFF Pharmaceuticals, Inc., Annual General Meeting, Nov 21, 2023

Aaron Fletcher Advises TFF Pharmaceuticals, Inc. of His Decision Not to Stand for Reelection to the Board

Consensus revenue estimates increase by 37%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 21%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

No longer forecast to breakeven

No longer forecast to breakeven

Key Executive recently bought US$132k worth of stock

Consensus revenue estimates increase by 16%

TFF Pharmaceuticals, Inc. Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer

TFF Pharmaceuticals, Inc. Appoints Zamaneh Mikhak as Chief Medical Officer

Forecast to breakeven in 2025

Key Executive recently bought US$53k worth of stock

TFF Pharmaceuticals Announces Leadership Transition

Consensus revenue estimates increase by 98%

Third quarter 2022 earnings released: US$0.29 loss per share (vs US$0.34 loss in 3Q 2021)

High number of new and inexperienced directors

Price target decreased to US$16.00

TFF Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

TFF Pharmaceuticals, Inc. Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program

TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting

Independent Director exercised options and sold US$72k worth of stock

Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

TFF Pharmaceuticals Announces Acceptance of Multiple Abstracts Featuring Applications of Thin Film Freezing Technology at the Upcoming AAPS PharmSci 360 Meeting

TFF Pharmaceuticals, Inc., Annual General Meeting, Nov 07, 2022

TFF Pharmaceuticals, Inc. Announces Presentation of Patient Data with Voriconazole Inhalation Powder At the 15Th International Congress on Lung Transplantation

TFF Pharma: The Potential Is Still Very Much Present

Consensus revenue estimates fall by 84%

No longer forecast to breakeven

No longer forecast to breakeven

Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.18 loss in 2Q 2021)

TFF Pharmaceuticals: Q3 Data Is Pivotal In So Many Ways

TFF Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022